(Q46147447)

19 December 2017

title

Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results (English)

1 reference

19 December 2017

1 reference

S Sacu

1

1 reference

19 December 2017

S Michels

2

1 reference

19 December 2017

F Prager

3

1 reference

19 December 2017

G Weigert

4

1 reference

19 December 2017

R Dunavoelgyi

5

1 reference

19 December 2017

W Geitzenauer

6

1 reference

19 December 2017

C Pruente

7

1 reference

19 December 2017

U Schmidt-Erfurth

8

1 reference

19 December 2017

language of work or name

1 reference

1 December 2009

1 reference

19 December 2017

published in

Eye

1 reference

19 December 2017

volume

23

1 reference

19 December 2017

issue

12

1 reference

19 December 2017

page(s)

2223-2227

1 reference

19 December 2017

Ranibizumab for neovascular age-related macular degeneration

cites work

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.423

Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.423

The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.423

Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.423

Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.423

Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.423

Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.423

Changes in confocal indocyanine green angiography through two years after photodynamic therapy with verteporfin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.423

Cytotoxicity of triamcinolone acetonide on human retinal pigment epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.423

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.423

Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.423

7 January 2021

inferred from DOI database lookup

The effect of short-term exposure of triamcinolone acetonide on fibroblasts and retinal pigment epithelial cells

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.423

7 January 2021

inferred from DOI database lookup

Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2008.423

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/EYE.2008.423

1 reference

19 December 2017

release_ckqnr7yrkza3tfm3izcfdujt6q

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ckqnr7yrkza3tfm3izcfdujt6q

24 November 2022

mapped directly with Wikidata item

1 reference

19 December 2017